Last reviewed · How we verify
Tranexamic acid tablets
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing blood clot breakdown and promoting hemostasis.
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing blood clot breakdown and promoting hemostasis. Used for Reduction of blood loss in surgical procedures, Treatment of heavy menstrual bleeding, Prevention and treatment of bleeding in hemophilia patients.
At a glance
| Generic name | Tranexamic acid tablets |
|---|---|
| Also known as | Oral administration of tranexamic acid, Lysteda, XP12B, Kapron(R), Lysteda, Cyklokapron |
| Sponsor | Carlos A Acosta-Olivo |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | Phase 3 |
Mechanism of action
Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, the key enzymes responsible for breaking down fibrin clots. By preventing the conversion of plasminogen to plasmin, it stabilizes formed clots and reduces excessive bleeding. This antifibrinolytic mechanism makes it useful in conditions characterized by excessive or prolonged bleeding.
Approved indications
- Reduction of blood loss in surgical procedures
- Treatment of heavy menstrual bleeding
- Prevention and treatment of bleeding in hemophilia patients
- Traumatic hemorrhage
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Nausea and vomiting
- Diarrhea
- Headache
- Visual disturbances
Key clinical trials
- Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma (NA)
- Tranexamic Acid for The Treatment of Gastrointestinal Bleeding (NA)
- Hemoglobin Drop and Need for Blood Transfusion in Primary Knee Arthroplasty With or Without Drain Insertion (NA)
- Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty (NA)
- Prevention of Postpartum Hemorrhage With Tranexamic Acid (PHASE2)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tranexamic acid tablets CI brief — competitive landscape report
- Tranexamic acid tablets updates RSS · CI watch RSS
- Carlos A Acosta-Olivo portfolio CI